Bausch Health Companies Inc. (BVF.F)
| Previous Close | 6.69 |
| Open | 6.34 |
| Bid | 6.34 x 31000 |
| Ask | 6.50 x 31000 |
| Day's Range | 6.34 - 6.34 |
| 52 Week Range | 5.55 - 9.82 |
| Volume | |
| Avg. Volume | 48 |
| Market Cap | 2.324B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | N/A |
- ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit ...
- ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare ...
- ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to ...
